24/7 Wall Street
17 Oct 2025, 15:05 UTC · 47w ago
Verdict
Headline takes no side. We score NVO −0.60 across five claims — strongly bearish.
−0.60strongly bearish
More negative than 82% of ticker scores this week
What the story claims
5 claims · scored −1 bearish … +1 bullish
President Trump stated that GLP-1 drug prices could be lowered to approximately $150 out-of-pocket monthly.
So whatDirectly threatens the premium pricing model that drives the massive revenues and high gross margins for Novo Nordisk and Eli Lilly.
More negative than 98% of claims this week
The U.S. government is pursuing the Most Favored Nation (MFN) policy to tie U.S. drug prices to lower international benchmarks.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 3 movers · tap to explore
More negative than 91% of claims this week
JPMorgan estimates a 50% price cut could trim Novo Nordisk's annual profits by $5 billion.
So whatProvides a concrete quantitative downside to earnings, justifying a valuation rerating for the company.
More negative than 86% of claims this week
Eli Lilly's Zepbound sales could fall 30% to 40% in the short term due to forced price reductions.
So whatSignals a significant immediate revenue hit and a potential delay in funding for future R&D, such as oral GLP-1 trials.
More negative than 80% of claims this week
Some analysts, including those at BMO Capital, argue that the current stock sell-off is 'overdone' because many insured patients already pay low rates via rebates.
More positive than 54% of claims this week
Which stocks this story touches
More negative than 82% of ticker scores this week
Shares fell over 4% due to threats from the Trump administration to drastically lower GLP-1 drug prices.
More negative than 79% of ticker scores this week
Shares declined 2.6% as government pressure on drug pricing threatens core margins and future R&D funding.
More negative than 69% of ticker scores this week
Mentioned as falling due to profit taking following earnings.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
MarketBeat
45m ago
−25.2%
Price agrees with the score
$41.98 vs $56.09 close before publication (Oct 16) · not market-adjusted
NVO chart →
